{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:13:01Z","timestamp":1793056381282,"version":"4.5.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s42000-025-00708-5","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:32:50Z","timestamp":1754487170000},"page":"923-946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["EndoBridge 2024: pearls and highlights"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-7662","authenticated-orcid":false,"given":"Bulent Okan","family":"Yildiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Armeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysanthi","family":"Balodimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Ciudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Fr\u00fchbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada El-Hajj","family":"Fuleihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza B.","family":"Geer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"H\u00f6ybye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente Lomholt","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra B.","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AJ","family":"van der Lely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djuro","family":"Macut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Novac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duarte","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Pfeifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Radi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viral","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine A.","family":"Stratakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlies","family":"Treiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios N.","family":"Vrachnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"708_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s42000-024-00549-8","volume":"23","author":"BO Yildiz","year":"2024","unstructured":"Yildiz BO, Boguszewski CL, da Silva Boguszewski MC, Busetto L, Celik O et al (2024) EndoBridge 2023: highlights and pearls hormones. (Athens) 23:183\u2013204. https:\/\/doi.org\/10.1007\/s42000-024-00549-8","journal-title":"(Athens)"},{"key":"708_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3389\/fendo.2019.00339","volume":"10","author":"CDC Kamilaris","year":"2019","unstructured":"Kamilaris CDC, Stratakis CA (2019) Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Front Endocrinol (Lausanne) 10:339. https:\/\/doi.org\/10.3389\/fendo.2019.00339","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"708_CR3","doi-asserted-by":"publisher","first-page":"T195","DOI":"10.1530\/ERC-17-0243","volume":"24","author":"R Alrezk","year":"2017","unstructured":"Alrezk R, Hannah-Shmouni F, Stratakis CA (2017) MEN4 and CDKN1B mutations: the latest of the MEN syndromes. Endocr Relat Cancer 24(10):T195\u2013T208. https:\/\/doi.org\/10.1530\/ERC-17-0243","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"708_CR4","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1210\/jcem.86.9.7903","volume":"86","author":"CA Stratakis","year":"2001","unstructured":"Stratakis CA, Kirschner LS, Carney JA (2001) Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 86(9):4041\u20134046. https:\/\/doi.org\/10.1210\/jcem.86.9.7903","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR5","doi-asserted-by":"publisher","unstructured":"Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO et al (2014) Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation. N Engl J Med 18;371(25):2363-74. https:\/\/doi.org\/10.1056\/NEJMoa1408028","DOI":"10.1056\/NEJMoa1408028"},{"issue":"5","key":"708_CR6","doi-asserted-by":"publisher","first-page":"E710","DOI":"10.1210\/jc.2014-4297","volume":"100","author":"P Xekouki","year":"2015","unstructured":"Xekouki P, Szarek E, Bullova P, Giubellino A, Quezado M, Mastroyannis SA et al (2015) Pituitary adenoma with paraganglioma\/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metab 100(5):E710\u2013E719. https:\/\/doi.org\/10.1210\/jc.2014-4297","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR7","unstructured":"Larkin S, Ansorge O, Pathology And Pathogenesis of Pituitary Adenomas And Other Sellar Lesions (2017). Feb 15. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferr\u00e8re B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000\u2013. PMID: 28402620"},{"issue":"1","key":"708_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF et al (2024) Acromegaly consensus group. consensus on criteria for acromegaly diagnosis and remission. Pituitary 27(1):7\u201322. https:\/\/doi.org\/10.1007\/s11102-023-01360-1","journal-title":"Pituitary"},{"issue":"6","key":"708_CR9","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/cen.15060","volume":"100","author":"S Orme","year":"2016","unstructured":"Orme S, McNally R, James PW et al (2016) UK acromegaly register study group. Increased mortality in acromegaly is due to vascular and respiratory disease and is normalised by control of GH levels-A retrospective analysis from the UK acromegaly register 1970\u20132016. Clin Endocrinol (Oxf) 100(6):558\u2013564. https:\/\/doi.org\/10.1111\/cen.15060","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"708_CR10","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A et al (2018) European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1\u2013G24. https:\/\/doi.org\/10.1530\/EJE-17-0796","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"708_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack A, Dekkers OM, Petersenn S et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a European society of endocrinology (ESE) survey 2016. Eur J Endocrinol 178(3):265\u2013276. https:\/\/doi.org\/10.1530\/EJE-17-0933","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"708_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman P, Trouillas J, Losa M et al (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187(4):593\u2013605. https:\/\/doi.org\/10.1530\/EJE-22-0440","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"708_CR13","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","volume":"108","author":"P Burman","year":"2023","unstructured":"Burman P, Casar-Borota O, Perez-Rivas LG, Dekkers OM (2023) Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment. J Clin Endocrinol Metab 108(7):1585\u20131601. https:\/\/doi.org\/10.1210\/clinem\/dgad098","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR14","doi-asserted-by":"publisher","unstructured":"Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C (2020) How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers (Basel) 12(2). https:\/\/doi.org\/10.3390\/cancers12020514","DOI":"10.3390\/cancers12020514"},{"issue":"1","key":"708_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00401-024-02736-8","volume":"147","author":"AL Lin","year":"2024","unstructured":"Lin AL, Rudneva VA, Richards AL et al (2024) Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors. Acta Neuropathol 147(1):85. https:\/\/doi.org\/10.1007\/s00401-024-02736-8","journal-title":"Acta Neuropathol"},{"issue":"10","key":"708_CR16","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"Lin AL, Jonsson P, Tabar V et al (2018) Marked response of a hypermutated ACTH-Secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab 103(10):3925\u20133930. https:\/\/doi.org\/10.1210\/jc.2018-01347","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR17","doi-asserted-by":"publisher","unstructured":"Cooper DS, Biondi B (2012) Subclinical thyroid disease. Lancet 24;379(9821):1142-54. https:\/\/doi.org\/10.1016\/S0140-6736(11)60276-6","DOI":"10.1016\/S0140-6736(11)60276-6"},{"issue":"2","key":"708_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1001\/jama.2019.9052","volume":"322","author":"B Biondi","year":"2019","unstructured":"Biondi B, Cappola AR, Cooper DS (2019) Subclinical hypothyroidism. JAMA 322(2):153\u2013160","journal-title":"JAMA"},{"key":"708_CR19","doi-asserted-by":"publisher","unstructured":"Biondi B, Cooper DS (2018) Subclinical Hyperthyroidism. N Engl J Med 11;379(15):1485\u20131486. https:\/\/doi.org\/10.1056\/NEJMc1809627","DOI":"10.1056\/NEJMc1809627"},{"issue":"3","key":"708_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000438750","volume":"4","author":"B Biondi","year":"2015","unstructured":"Biondi B, Bartalena L, Cooper DS, Heged\u00fcs L, Laurberg P, Kahaly GJ (2015) The 2015 European thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J 4(3):149\u2013163. https:\/\/doi.org\/10.1159\/000438750","journal-title":"Eur Thyroid J"},{"key":"708_CR21","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae777","author":"B Biondi","year":"2024","unstructured":"Biondi B (2024) Atrial fibrillation and stroke: updated evidence on a screening program according to serum TSH. J Clin Endocrinol Metab:dgae777. https:\/\/doi.org\/10.1210\/clinem\/dgae777","journal-title":"J Clin Endocrinol Metab:dgae777"},{"issue":"1","key":"708_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0022-3476(03)00187-2","volume":"143","author":"W H\u00f6gler","year":"2003","unstructured":"H\u00f6gler W, Briody J, Woodhead HJ, Chan A, Cowell CT (2003) Importance of lean mass in the interpretation of total body densitometry in children and adolescents. J Pediatr 143(1):81\u201388. https:\/\/doi.org\/10.1016\/S0022-3476(03)00187-2","journal-title":"J Pediatr"},{"issue":"4","key":"708_CR23","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.bone.2004.06.009","volume":"35","author":"NJ Crabtree","year":"2004","unstructured":"Crabtree NJ, Kibirige MS, Fordham JN, Banks LM, Muntoni F, Chinn D, Boivin CM, Shaw NJ (2004) The relationship between lean body mass and bone mineral content in paediatric health and disease. Bone 35(4):965\u2013972. https:\/\/doi.org\/10.1016\/j.bone.2004.06.009","journal-title":"Bone"},{"key":"708_CR24","doi-asserted-by":"publisher","unstructured":"P\u0142udowski P, Lebiedowski M, Olszaniecka M, Marowska J, Matusik H, Lorenc RS (2006) Idiopathic juvenile osteoporosis\u2013an analysis of the muscle-bone relationship. Osteoporosis international, 2006. 17(11):1681-90. https:\/\/doi.org\/10.1007\/s00198-006-0183-1","DOI":"10.1007\/s00198-006-0183-1"},{"issue":"6","key":"708_CR25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1359\/jbmr.2002.17.6.1095","volume":"17","author":"E Schoenau","year":"2002","unstructured":"Schoenau E, Neu CM, Beck B, Manz F, Rauch F (2002) Bone mineral content per muscle cross-sectional area as an index of the functional muscle\u2010bone unit. J Bone Miner Res 17(6):1095\u20131101. https:\/\/doi.org\/10.1359\/jbmr.2002.17.6.1095","journal-title":"J Bone Miner Res"},{"issue":"1","key":"708_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocd.2020.01.006","volume":"24","author":"CE Guss","year":"2021","unstructured":"Guss CE, McAllister A, Gordon CM (2021) DXA in children and adolescents. J Clin Densitometry 24(1):28\u201335. https:\/\/doi.org\/10.1016\/j.jocd.2020.01.006","journal-title":"J Clin Densitometry"},{"issue":"5","key":"708_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R (2012) Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11(5):401\u2013419. https:\/\/doi.org\/10.1038\/nrd3705","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"708_CR28","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"708_CR29","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/jbmr.2480","volume":"30","author":"MS Ominsky","year":"2015","unstructured":"Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman RB, Baron R, Dempster DW (2015) Sustained Modeling-Based bone formation during adulthood in cynomolgus monkeys May contribute to continuous BMD gains with denosumab. J Bone Min Res 30(7):1280\u20131289. https:\/\/doi.org\/10.1002\/jbmr.2480","journal-title":"J Bone Min Res"},{"issue":"5","key":"708_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19(5):307\u2013317. https:\/\/doi.org\/10.1038\/s41584-023-00935-3","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"708_CR31","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"20","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 20(8):756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"issue":"9","key":"708_CR32","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97(9):3161\u20133169. https:\/\/doi.org\/10.1210\/jc.2012-1569","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"708_CR33","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","volume":"6","author":"KG Saag","year":"2018","unstructured":"Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double- dummy, non-inferiority study. Lancet Diabetes Endocrinol 6(6):445\u2013454. https:\/\/doi.org\/10.1016\/S2213-8587(18)30075-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"708_CR34","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS Solling","year":"2020","unstructured":"Solling AS, Harslof T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Min Res 35(10):1858\u20131870. https:\/\/doi.org\/10.1002\/jbmr.4098","journal-title":"J Bone Min Res"},{"key":"708_CR35","doi-asserted-by":"publisher","first-page":"115830","DOI":"10.1016\/j.bone.2020.115830","volume":"144","author":"J Everts-Graber","year":"2021","unstructured":"Everts-Graber J, Reichenbach S, Gahl B, Ziswiler HR, Studer U, Lehmann T (2021) Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study. Bone 144:115830. https:\/\/doi.org\/10.1016\/j.bone.2020.115830","journal-title":"Bone"},{"issue":"11","key":"708_CR36","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F, Huang S, McDermott M, Cummings SR (2022) Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Min Res 37(11):2112\u20132120. https:\/\/doi.org\/10.1002\/jbmr.4705","journal-title":"J Bone Min Res"},{"issue":"1","key":"708_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, DAPS Investigators (2012) Final results of the DAPS (Denosumab adherence preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23(1):317\u2013326. https:\/\/doi.org\/10.1007\/s00198-011-1780-1","journal-title":"Osteoporos Int"},{"issue":"12","key":"708_CR38","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-Year clinical trial. J Bone Min Res 34(12):2220\u20132228. https:\/\/doi.org\/10.1002\/jbmr.3853","journal-title":"J Bone Min Res"},{"issue":"7","key":"708_CR39","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS Solling","year":"2021","unstructured":"Solling AS, Harslof T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: A 2-Year randomized study. J Bone Min Res 36(7):1245\u20131254. https:\/\/doi.org\/10.1002\/jbmr.4305","journal-title":"J Bone Min Res"},{"key":"708_CR40","doi-asserted-by":"publisher","first-page":"dgaa756","DOI":"10.1210\/clinem\/dgaa756","volume":"26","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 26:dgaa756. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"708_CR41","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"26","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki M, Eastell R et al (2024) Goal-Directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Min Res 26(10):1393\u20131405. https:\/\/doi.org\/10.1093\/jbmr\/zjae119","journal-title":"J Bone Min Res"},{"key":"708_CR42","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1001\/jama.285.3.320","volume":"285","author":"R Lindsay","year":"2021","unstructured":"Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I et al (2021) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320\u2013323","journal-title":"JAMA"},{"key":"708_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","volume":"30","author":"A Balasubramanian","year":"2019","unstructured":"Balasubramanian A, Zhang J, Chen L, Wenkert D, Daigle SG et al (2019) Risk of subsequent fracture after prior fracture among older women. Osteoporos Int 30:79\u201392. https:\/\/doi.org\/10.1007\/s00198-018-4732-1","journal-title":"Osteoporos Int"},{"key":"708_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind,double dummy, randomised controlled trial. Lancet 391:230\u2013240. https:\/\/doi.org\/10.1016\/S0140-6736(17)32137-2","journal-title":"Lancet"},{"key":"708_CR45","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"3","key":"708_CR46","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1210\/clinem\/dgz162","volume":"105","author":"BZ Leder","year":"2020","unstructured":"Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS (2020) Effect of abaloparatide versus alendronate on fracture risk reduction in postmenopausal women with osteoporosis. J Clin Endo Metab 105(3):938\u2013943. https:\/\/doi.org\/10.1210\/clinem\/dgz162","journal-title":"J Clin Endo Metab"},{"key":"708_CR47","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Zanchetta JR, Russo L, Recknow CP, Saag KG et al (2012) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int 23:2141\u20132150. https:\/\/doi.org\/10.1007\/s00198-011-1856-y","journal-title":"Osteoporos Int"},{"key":"708_CR48","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Marin F, Donley DW et al (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028\u20132039. https:\/\/doi.org\/10.1056\/NEJMoa071408","journal-title":"N Engl J Med"},{"key":"708_CR49","doi-asserted-by":"publisher","unstructured":"Cosman F, Oates M, Betah D, Timoshanko J, Wang Z et al (2024) Romosozumab Followed by Denosumab Versus Denosumab Only: A Post-hoc Analysis of FRAME and FRAME Extension, J Bone Mineral Res 2;39(9):1268\u20131277. https:\/\/doi.org\/10.1093\/jbmr\/zjae116","DOI":"10.1093\/jbmr\/zjae116"},{"issue":"7","key":"708_CR50","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41574-019-0197-3","volume":"15","author":"L Ringholm","year":"2019","unstructured":"Ringholm L, Damm P, Mathiesen ER (2019) Improving pregnancy outcomes in women with diabetes mellitus: modern management. Nat Rev Endocrinol 15(7):406\u2013416. https:\/\/doi.org\/10.1038\/s41574-019-0197-3","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"708_CR51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S2213-8587(20)30406-X","volume":"9","author":"HR Murphy","year":"2021","unstructured":"Murphy HR, Howgate C, O\u2019Keefe J, Myers J, Morgan M, Coleman MA, Jolly M, Valabhji J, Scott EM, Knighton P, Young B, Lewis-Barned N, National Pregnancy in Diabetes (NPID) advisory group (2021) Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year National population-based cohort study. Lancet Diabetes Endocrinol 9(3):153\u2013164. https:\/\/doi.org\/10.1016\/S2213-8587(20)30406-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"708_CR52","doi-asserted-by":"publisher","first-page":"e14789","DOI":"10.1111\/dme.14789","volume":"39","author":"J Bahrami","year":"2022","unstructured":"Bahrami J, Tomlinson G, Murphy HR, Feig DS, CONCEPTT Collaborative Group (2022) Impaired awareness of hypoglycaemia in women with type 1 diabetes in pregnancy: hypoglycaemia fear, glycaemic and pregnancy outcomes. Diabet Med 39(5):e14789. https:\/\/doi.org\/10.1111\/dme.14789","journal-title":"Diabet Med"},{"issue":"7","key":"708_CR53","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S2213-8587(23)00116-X","volume":"11","author":"K Benhalima","year":"2023","unstructured":"Benhalima K, Beunen K, Siegelaar SE, Painter R, Murphy HR, Feig DS, Donovan LE, Polsky S, Buschur E, Levy CJ, Kudva YC, Battelino T, Ringholm L, Mathiesen ER, Mathieu C (2023) Management of type 1 diabetes in pregnancy: update on lifestyle, Pharmacological treatment, and novel technologies for achieving glycaemic targets. Lancet Diabetes Endocrinol 11(7):490\u2013508. https:\/\/doi.org\/10.1016\/S2213-8587(23)00116-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"708_CR54","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1056\/NEJMoa2303911","volume":"26","author":"TTM Lee","year":"2023","unstructured":"Lee TTM, Collett C, Bergford S, Hartnell S, Scott EM, Lindsay RS, Hunt KF, McCance DR, Barnard-Kelly K, Rankin D, Lawton J, Reynolds RM, Flanagan E, Hammond M, Shepstone L, Wilinska ME, Sibayan J, Kollman C, Beck R, Hovorka R, Murphy HR, AiDAPT Collaborative Group (2023) Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. N Engl J Med 26(17):1566\u20131578. https:\/\/doi.org\/10.1056\/NEJMoa2303911","journal-title":"N Engl J Med"},{"issue":"3","key":"708_CR55","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.6084\/m9.figshare.5986948","volume":"9","author":"L Blonde","year":"2018","unstructured":"Blonde L, Meneghini L, Peng XV et al (2018) Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA. Diabetes Ther 9(3):1347\u20131358. https:\/\/doi.org\/10.6084\/m9.figshare.5986948","journal-title":"Diabetes Ther"},{"key":"708_CR56","doi-asserted-by":"publisher","first-page":"204201881984469","DOI":"10.1177\/2042018819844694","volume":"3","author":"S Khunti","year":"2019","unstructured":"Khunti S, Khunti K, Seidu S (2019) Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab 3:10:2042018819844694. https:\/\/doi.org\/10.1177\/2042018819844694","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"3","key":"708_CR57","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/endrev\/bnad037","volume":"45","author":"J Rosenstock","year":"2024","unstructured":"Rosenstock J, Juneja R, Beals JM, Moyers JS, Ilag L, McCrimmon RJ (2024) The basis for weekly insulin therapy: evolving evidence with insulin Icodec and insulin Efsitora Alfa. Endocr Rev 45(3):379\u2013413. https:\/\/doi.org\/10.1210\/endrev\/bnad037","journal-title":"Endocr Rev"},{"issue":"8","key":"708_CR58","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.3390\/biomedicines12081852","volume":"12","author":"G Lisco","year":"2024","unstructured":"Lisco G, De Tullio A, De Geronimo V, Giagulli VA, Guastamacchia E, Piazzolla G, Disoteo OE, Triggiani V (2024) Once-Weekly insulin Icodec in diabetes mellitus: A systematic review and Meta-Analysis of randomized clinical trials (ONWARDS clinical Program). Biomedicines 12(8):1852. https:\/\/doi.org\/10.3390\/biomedicines12081852","journal-title":"Biomedicines"},{"issue":"10458","key":"708_CR59","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S0140-6736(24)01804-X","volume":"404","author":"RM Bergenstal","year":"2024","unstructured":"Bergenstal RM, Weinstock RS, Mathieu C, Onishi Y, Vijayanagaram V, Katz ML, Carr MC, Chang AM (2024) Once-weekly insulin Efsitora Alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial. Lancet 404(10458):1132\u20131142. https:\/\/doi.org\/10.1016\/S0140-6736(24)01804-X","journal-title":"Lancet"},{"key":"708_CR60","doi-asserted-by":"publisher","unstructured":"Li P, Li Z, Staton E, Umpierrez GE, Davis G, Shao H, Pasquel FJ (2024) GLP-1 Receptor Agonist and SGLT2 Inhibitor Prescribing in People With Type 1 Diabetes. JAMA 19;332(19):1667\u20131669. https:\/\/doi.org\/10.1001\/jama.2024.18581","DOI":"10.1001\/jama.2024.18581"},{"issue":"10","key":"708_CR61","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s00125-023-05980-x","volume":"66","author":"C Mathieu","year":"2023","unstructured":"Mathieu C, Ahmadzai I (2023) Incretins beyond type 2 diabetes. Diabetologia 66(10):1809\u20131819. https:\/\/doi.org\/10.1007\/s00125-023-05980-x","journal-title":"Diabetologia"},{"issue":"6","key":"708_CR62","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1159\/000527653","volume":"96","author":"T Hropot","year":"2023","unstructured":"Hropot T, Battelino T, Dovc K (2023) Sodium-Glucose Co-Transporter-2 inhibitors in type 1 diabetes: A scoping review. Horm Res Paediatr 96(6):620\u2013630. https:\/\/doi.org\/10.1159\/000527653Epub 2022 Oct 24","journal-title":"Horm Res Paediatr"},{"key":"708_CR63","doi-asserted-by":"publisher","unstructured":"Stougaard EB, Rossing P, Cherney D, Vistisen D, Persson F (2022) Sodium-glucose otransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines. J Diabetes Complications. 2022;36(8):108257. https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108257","DOI":"10.1016\/j.jdiacomp.2022.108257"},{"issue":"7","key":"708_CR64","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/dia.2021.0553","volume":"24","author":"MM Visser","year":"2022","unstructured":"Visser MM, Mathieu C, Gillard P (2022) Diabetic ketoacidosis after Sodium-Glucose cotransporter inhibitor initiation under advanced hybrid Closed-Loop therapy in type 1 diabetes. Diabetes Technol Ther 24(7):516\u2013519. https:\/\/doi.org\/10.1089\/dia.2021.0553","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"708_CR65","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41574-024-00973-1","volume":"20","author":"RA Ajjan","year":"2024","unstructured":"Ajjan RA, Battelino T, Cos X, Del Prato S, Philips JC, Meyer L, Seufert J, Seidu S (2024) Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nat Rev Endocrinol 20(7):426\u2013440. https:\/\/doi.org\/10.1038\/s41574-024-00973-1","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"708_CR66","doi-asserted-by":"publisher","first-page":"e230108","DOI":"10.1530\/EC-23-0108","volume":"27","author":"K Lingen","year":"2023","unstructured":"Lingen K, Pikounis T, Bellini N, Isaacs D (2023) Advantages and disadvantages of connected insulin pens in diabetes management. Endocr Connect 27(11):e230108. https:\/\/doi.org\/10.1530\/EC-23-0108","journal-title":"Endocr Connect"},{"issue":"Supplement1","key":"708_CR67","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.2337\/db24-1904-LB","volume":"73","author":"1904-LB","year":"2024","unstructured":"1904-LB (2024) Glycemic improvement with use of the omnipod 5 automated insulin delivery system in adults with type 2 Diabetes\u2014Results of the SECURE-T2D pivotal trial. Diabetes 73(Supplement_1):1904\u2013LB. https:\/\/doi.org\/10.2337\/db24-1904-LB","journal-title":"Diabetes"},{"issue":"7","key":"708_CR68","doi-asserted-by":"publisher","first-page":"e14218","DOI":"10.1111\/eci.14218","volume":"54","author":"M Aguas-Ayesa","year":"2024","unstructured":"Aguas-Ayesa M, Y\u00e1rnoz-Esquiroz P, Perdomo CM, Olazar\u00e1n L, Vegas-Aguilar IM, Garc\u00eda-Almeida JM et al (2024) Revisiting the beyond BMI paradigm in excess weight diagnosis and management: A call to action. Eur J Clin Invest 54(7):e14218","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"708_CR69","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000368783","volume":"7","author":"JE Blundell","year":"2014","unstructured":"Blundell JE, Dulloo AG, Salvador J, Fr\u00fchbeck G, EASO SAB Working Group on BMI (2014) Beyond BMI\u2013phenotyping the obesities. Obes Facts 7(5):322\u2013328. https:\/\/doi.org\/10.1159\/000368783","journal-title":"Obes Facts"},{"issue":"2","key":"708_CR70","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000497124","volume":"12","author":"G Fr\u00fchbeck","year":"2019","unstructured":"Fr\u00fchbeck G, Busetto L, Dicker D, Yumuk V, Goossens GH, Hebebrand J et al (2019) The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications. Obes Facts 12(2):131\u2013136. https:\/\/doi.org\/10.1159\/000497124","journal-title":"Obes Facts"},{"issue":"2","key":"708_CR71","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1096\/fj.00-0249com","volume":"15","author":"G Fr\u00fchbeck","year":"2001","unstructured":"Fr\u00fchbeck G, G\u00f3mez Ambrosi J, Salvador J (2001) Leptin-induced lipolysis opposes the tonic Inhibition of endogenous adenosine in white adipocytes. FASEB J 15(2):333\u2013340. https:\/\/doi.org\/10.1096\/fj.00-0249com","journal-title":"FASEB J"},{"issue":"9","key":"708_CR72","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1210\/en.2002-220075","volume":"143","author":"A Fortu\u00f1o","year":"2002","unstructured":"Fortu\u00f1o A, Rodr\u00edguez A, G\u00f3mez-Ambrosi J, Mu\u00f1iz P, Salvador J, D\u00edez J et al (2002) Leptin inhibits angiotensin II-induced intracellular calcium increase and vasoconstriction in the rat aorta. Endocrinology 143(9):3555\u20133560. https:\/\/doi.org\/10.1210\/en.2002-220075","journal-title":"Endocrinology"},{"issue":"3","key":"708_CR73","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2174\/1568016043356255","volume":"2","author":"G Fr\u00fchbeck","year":"2004","unstructured":"Fr\u00fchbeck G (2004) The adipose tissue as a source of vasoactive factors. Curr Med Chem - Cardiovasc Hematol Agents 2(3):197\u2013208. https:\/\/doi.org\/10.2174\/1568016043356255","journal-title":"Curr Med Chem - Cardiovasc Hematol Agents"},{"issue":"11","key":"708_CR74","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/ijo.2014.31","volume":"38","author":"S Heinonen","year":"2014","unstructured":"Heinonen S, Saarinen L, Naukkarinen J, Rodr\u00edguez A, Fr\u00fchbeck G, Hakkarainen A et al (2014) Adipocyte morphology and implications for metabolic derangements in acquired obesity. Int J Obes (Lond) 38(11):1423\u20131431. https:\/\/doi.org\/10.1038\/ijo.2014.31","journal-title":"Int J Obes (Lond)"},{"issue":"5","key":"708_CR75","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11154-023-09797-2","volume":"24","author":"CM Perdomo","year":"2023","unstructured":"Perdomo CM, Avil\u00e9s-Olmos I, Dicker D, Fr\u00fchbeck G (2023) Towards an adiposity-related disease framework for the diagnosis and management of obesities. Rev Endocr Metab Disord 24(5):795\u2013807. https:\/\/doi.org\/10.1007\/s11154-023-09797-2","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"708_CR76","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11154-023-09829-x","volume":"24","author":"P Portincasa","year":"2023","unstructured":"Portincasa P, Fr\u00fchbeck G (2023) Phenotyping the obesities: reality or utopia? Rev Endocr Metab Disord 24(5):767\u2013773. https:\/\/doi.org\/10.1007\/s11154-023-09829-x","journal-title":"Rev Endocr Metab Disord"},{"issue":"7","key":"708_CR77","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/obr.12551","volume":"18","author":"GA Bray","year":"2017","unstructured":"Bray GA, Kim KK, Wilding JPH, World Obesity Federation (2017) Obesity: a chronic relapsing progressive disease process. A position statement of the world obesity. Federation Obes Rev 18(7):715\u2013723. https:\/\/doi.org\/10.1111\/obr.12551","journal-title":"Federation Obes Rev"},{"issue":"17","key":"708_CR78","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","volume":"27","author":"P Sumithran","year":"2011","unstructured":"Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J (2011) Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 27(17):1597\u20131604. https:\/\/doi.org\/10.1056\/NEJMoa1105816","journal-title":"N Engl J Med"},{"key":"708_CR79","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"PH John","year":"2021","unstructured":"John PH, Wilding, Rachel L (2021) Batterham, Salvatore Calanna et al for the STEP 1 study group efficacy and safety of Once-weekly semaglutide 2.4\u00a0mg in adults with overweight or obesity N. Engl J Med 384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"Engl J Med"},{"key":"708_CR80","doi-asserted-by":"publisher","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torn\u00f8e CW, Ryan DH, SELECT Trial Investigators (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 14;389(24):2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","DOI":"10.1056\/NEJMoa2307563"},{"key":"708_CR81","doi-asserted-by":"publisher","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 21;387(3):205\u2013216 https:\/\/doi.org\/10.1056\/NEJMoa2206038","DOI":"10.1056\/NEJMoa2206038"},{"issue":"3","key":"708_CR82","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) (2024) Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"issue":"9","key":"708_CR83","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","volume":"30","author":"L Busetto","year":"2024","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, Halford JCG, Sbraccia P, Yumuk V, Goossens GH (2024) A new framework for the diagnosis, staging and management of obesity in adults. Nat Med 30(9):2395\u20132399. https:\/\/doi.org\/10.1038\/s41591-024-03095-3","journal-title":"Nat Med"},{"key":"708_CR84","doi-asserted-by":"publisher","first-page":"111675","DOI":"10.1016\/j.diabres.2024.111675","volume":"211","author":"B Brouwers","year":"2024","unstructured":"Brouwers B, Rao G, Tang Y, Rodr\u00edguez \u00c1, Glass LC, Hartman ML (2024) Incretin-based investigational therapies for the treatment of MASLD\/MASH. Diabetes Res Clin Pract 211:111675. https:\/\/doi.org\/10.1016\/j.diabres.2024.111675","journal-title":"Diabetes Res Clin Pract"},{"issue":"25","key":"708_CR85","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"20","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA (2022) The global burden of cardiovascular diseases and risk: A compass for future health. J Am Coll Cardiol 20(25):2361\u20132371. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.005","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"708_CR86","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"14","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torn\u00f8e CW, Ryan DH, SELECT Trial Investigators (2023) N Engl J Med 14(24):2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"issue":"10454","key":"708_CR87","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"24","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, Hovingh GK, Hardt-Lindberg S, Frenkel O, Weeke PE, Rasmussen S, Goudev A, Lang CC, Urina-Triana M, Pietil\u00e4 M, Lincoff AM, SELECT Trial Investigators (2024) Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet 24(10454):773\u2013786. https:\/\/doi.org\/10.1016\/S0140-6736(24)01498-3","journal-title":"Lancet"},{"issue":"3","key":"708_CR88","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/cen.14558","volume":"97","author":"N Helvaci","year":"2022","unstructured":"Helvaci N, Yildiz BO (2022) The impact of ageing and menopause in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 97(3):371\u2013382. https:\/\/doi.org\/10.1111\/cen.14558","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"708_CR89","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/humupd\/dmad015","volume":"2","author":"M Millan-de-Meer","year":"2023","unstructured":"Millan-de-Meer M, Luque-Ramirez M, Nattero-Chavez L, Escobar-Morreale HF (2023) PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis. Hum Reprod Update Nov 2(6):741\u2013772. https:\/\/doi.org\/10.1093\/humupd\/dmad015","journal-title":"Hum Reprod Update Nov"},{"issue":"10","key":"708_CR90","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","volume":"18","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE (2023) Recommendations from the 2023 international Evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab 18(10):2447\u20132469. https:\/\/doi.org\/10.1210\/clinem\/dgad463","journal-title":"J Clin Endocrinol Metab"},{"key":"708_CR91","doi-asserted-by":"publisher","unstructured":"Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM Jr, Wang Q, Wolski K, Davey D, Kalahasti V, Khan N, Miller MG, Snabes MC, Chan A, Dubcenco E, Li X, Yi T, Huang B, Pencina KM, Travison TG, Nissen SE, TRAVERSE Study Investigators. (2023) Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med 13;389(2):107\u2013117 https:\/\/doi.org\/10.1056\/NEJMoa2215025","DOI":"10.1056\/NEJMoa2215025"},{"issue":"2","key":"708_CR92","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0911101","volume":"8","author":"FC Wu","year":"2010","unstructured":"Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O\u2019Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT, EMAS Group (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 8(2):123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa0911101","journal-title":"N Engl J Med"},{"key":"708_CR93","doi-asserted-by":"publisher","unstructured":"Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, Testosterone Trials Investigators (2016) Effects of testosterone treatment in older men. N Engl J Med 18(3747):611\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1506119","DOI":"10.1056\/NEJMoa1506119"},{"issue":"4","key":"708_CR94","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/andr.12502","volume":"6","author":"GM Colpi","year":"2018","unstructured":"Colpi GM, Francavilla S, Haidl G, Link K, Behre HM, Goulis DG, Krausz C, Giwercman A (2018) European academy of andrology: management of oligo-astheno-teratozoospermia. Andrology 6(4):513\u2013524. https:\/\/doi.org\/10.1111\/andr.12502","journal-title":"Andrology"},{"issue":"2","key":"708_CR95","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ (2016) Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101(2):364\u2013389. https:\/\/doi.org\/10.1210\/jc.2015-1710","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"708_CR96","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-14-0253","volume":"171","author":"G Conway","year":"2014","unstructured":"Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz BO, ESE PCOS Special Interest Group (2014) The polycystic ovary syndrome: a position statement from the European society of endocrinology. Eur J Endocrinol 171(4):P1\u201329. https:\/\/doi.org\/10.1530\/EJE-14-0253","journal-title":"Eur J Endocrinol"},{"key":"708_CR97","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000342179","volume":"40","author":"D Pignatelli","year":"2013","unstructured":"Pignatelli D (2013) Non-classic adrenal hyperplasia due to the deficiency of 21-hydroxylase and its relation to polycystic ovarian syndrome. Front Horm Res 40:158\u2013170. https:\/\/doi.org\/10.1159\/000342179","journal-title":"Front Horm Res"},{"issue":"2","key":"708_CR98","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/ejendo\/lvae085","volume":"5","author":"S Livadas","year":"2024","unstructured":"Livadas S, Yildiz BO, Mastorakos G, Gambineri A, Pignatelli D, Giorgino F, Andersen MS, Obermayer-Pietsch B, Macut D, ESE PCOS Special Interest Group (2024) European survey of diagnosis and management of the polycystic ovary syndrome: full report on the ESE PCOS special interest group\u2019s 2023 questionnaire. Eur J Endocrinol 5(2):134\u2013143. https:\/\/doi.org\/10.1093\/ejendo\/lvae085","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"708_CR99","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.fertnstert.2003.10.004","volume":"81","author":"ESHRE Rotterdam","year":"2004","unstructured":"Rotterdam ESHRE, ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81(1):19\u201325. https:\/\/doi.org\/10.1016\/j.fertnstert.2003.10.004","journal-title":"Fertil Steril"},{"issue":"2","key":"708_CR100","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s0950-351x","volume":"10","author":"J Holte","year":"1996","unstructured":"Holte J (1996) Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome. Baillieres Clin Endocrinol Metab 10(2):221\u2013247. https:\/\/doi.org\/10.1016\/s0950-351x","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"708_CR101","doi-asserted-by":"publisher","unstructured":"Carmina E (2022) Need to Introduce the Finding of Obesity or Normal Body Weight in the Current Diagnostic Criteria and in the Classification of PCOS. Diagnostics (Basel). 21;12(10):2555. https:\/\/doi.org\/10.3390\/diagnostics12102555","DOI":"10.3390\/diagnostics12102555"},{"key":"708_CR102","doi-asserted-by":"publisher","unstructured":"Helvaci N, Yildiz BO (2024) Polycystic ovary syndrome as a metabolic disease. Nat Rev Endocrinol Nov 28. https:\/\/doi.org\/10.1038\/s41574-024-01057-w","DOI":"10.1038\/s41574-024-01057-w"},{"issue":"12","key":"708_CR103","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diagnostics13122067","volume":"13","author":"S Livadas","year":"2023","unstructured":"Livadas S, Paparodis R, Anagnostis P, Gambineri A, Bjeki\u0107-Macut J, Petrovi\u0107 T, Yildiz BO, Mici\u0107 D, Mastorakos G, Macut D (2023) Assessment of type 2 diabetes risk in young women with polycystic ovary syndrome. Diagnostics (Basel) 13(12):14. https:\/\/doi.org\/10.3390\/diagnostics13122067","journal-title":"Diagnostics (Basel)"},{"key":"708_CR104","doi-asserted-by":"publisher","unstructured":"Aydogan Mathyk B, Cetin E, Yildiz BO (2022) Use of anti-M\u00fcllerian hormone for understanding ovulatory dysfunction in polycystic ovarian syndrome. Curr Opin Endocrinol Diabetes Obes 1;29(6):528\u2013534. https:\/\/doi.org\/10.1097\/MED.0000000000000772","DOI":"10.1097\/MED.0000000000000772"},{"issue":"3","key":"708_CR105","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.rbmo.2019.04.002","volume":"39","author":"G Bozdag","year":"2019","unstructured":"Bozdag G, Mumusoglu S, Coskun ZY, Yarali H, Yildiz BO (2019) Anti-M\u00fcllerian hormone as a diagnostic tool for PCOS under different diagnostic criteria in an unselected population. Reprod Biomed Online 39(3):522\u2013529. https:\/\/doi.org\/10.1016\/j.rbmo.2019.04.002","journal-title":"Reprod Biomed Online"},{"issue":"9","key":"708_CR106","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/humrep\/dead156","volume":"5","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE, International PCOS Network (2023) Recommendations from the 2023 international Evidence-based guideline for the assessment and management of polycystic. Ovary Syndrome Hum Reprod 5(9):1655\u20131679. https:\/\/doi.org\/10.1093\/humrep\/dead156","journal-title":"Ovary Syndrome Hum Reprod"},{"key":"708_CR107","doi-asserted-by":"publisher","unstructured":"Giannetta E, Sesti F, Modica R, Grossrubatscher EM, Ragni A, Zanata I, Colao A, Faggiano A (2022) What Lies Behind Paraneoplastic Hypercalcemia Secondary to Well-Differentiated Neuroendocrine Neoplasms? A Systematic Review of the Literature. J Pers Med 21;12(10):1553. https:\/\/doi.org\/10.3390\/jpm12101553","DOI":"10.3390\/jpm12101553"},{"issue":"4","key":"708_CR108","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1053\/j.semdp.2019.03.002","volume":"36","author":"J Guilmette","year":"2019","unstructured":"Guilmette J, Nos\u00e9 V (2019) Paraneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms. Semin Diagn Pathol 36(4):229\u2013239. https:\/\/doi.org\/10.1053\/j.semdp.2019.03.002","journal-title":"Semin Diagn Pathol"},{"issue":"12","key":"708_CR109","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/cells13121051","volume":"18","author":"P Bartkiewicz","year":"2024","unstructured":"Bartkiewicz P, Kunachowicz D, Filipski M, Stebel A, Ligoda J, Rembia\u0142kowska N (2024) Hypercalcemia in cancer: causes, effects, and treatment strategies. Cells 18(12):1051. https:\/\/doi.org\/10.3390\/cells13121051","journal-title":"Cells"},{"issue":"9","key":"708_CR110","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1210\/jc.2014-1315","volume":"99","author":"K Kamp","year":"2014","unstructured":"Kamp K, Feelders RA, van Adrichem RC, de Rijke YB, van Nederveen FH, Kwekkeboom DJ, de Herder WW (2014) Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up. J Clin Endocrinol Metab 99(9):3060\u20133069. https:\/\/doi.org\/10.1210\/jc.2014-1315","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"708_CR111","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol 19(12):722\u2013740","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"708_CR112","doi-asserted-by":"publisher","first-page":"e13169","DOI":"10.1111\/jne.13169","volume":"34","author":"H Lasolle","year":"2022","unstructured":"Lasolle H, Vasiljevic A, Jouanneau E, Ilie MD, Raverot G (2022) Aggressive corticotroph tumors and carcinomas. J Neuroendocrinol 34(8):e13169","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"708_CR113","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V et al (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187(4):593\u2013605","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"708_CR114","doi-asserted-by":"publisher","first-page":"101712","DOI":"10.1016\/j.beem.2022.101712","volume":"36","author":"G Raverot","year":"2022","unstructured":"Raverot G, Ilie MD (2022) Immunotherapy in pituitary carcinomas and aggressive pituitary tumors. Best Pract Res Clin Endocrinol Metab 36(6):101712","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-025-00708-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-025-00708-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-025-00708-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T18:02:40Z","timestamp":1764871360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-025-00708-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":114,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1007\/s42000-025-00708-5","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.O.Y., O.C., DY, G.H, A.J.L., M.P, D.P, B.B., D.M., D.N.V., D.G., and C.B. have no relevant disclosures to report. V.S. has received research support from Alexion, Novo Nordisk, Dexcom, Breakthrough T1D, and NIH (NIDDK\/NIAMS) and consulting, speaking, or advisory board from Dexcom, Insulet, Tandem Diabetes Care, Ascensia Diabetes Care, Embecta, Lilly, Sanofi, Novo Nordisk, Sequel Med Tech, Biomea Fusion, Lumosfit, and Genomelink. C.G. Present: Wolters Kluwer\u2013 royalties as textbook editor. Past: Gilead Sciences\u2013 consulting fees (for pediatric HIV bone density trial). J.K.M is a member of advisory boards of Abbott Diabetes Care, Biomea Fusion, Dexcom Inc., Boehringer Ingelheim, Eli Lilly, Embecta, Medtronic, Novo Nordisk A\/S, Pharmasens, Roche Diabetes Care, and Sanofi-Aventis and received speaker honoraria from A. Menarini Diagnostics, Abbott Diabetes Care, Dexcom, Eli Lilly, Novo Nordisk A\/S, Roche Diabetes Care, and Sanofi. She is shareholder of decide Clinical Software GmbH and Elyte Diagnostics and serves as CMO of Elyte Diagnostics. B.M was a PI in the SELECT trial. Else her interests are Reset Health shareholder Advisory Novo Nordisk, Lilly, Astra Zeneca Speaking bureau: Novo Nordisk, Lilly, and Amgen. B.L. has received research grants from Amgen, advisory boards, consultancy, and speaker bureaus from Amgen, UCB, Mereo, Samsung-Bioepis, Angitia, Entero-Bio, and Gideon-Richter. P.G. has received financial compensation from Medtronic in connection with preparing and delivering this presentation. E.G has commercial interest with Amryt\/Chiesi; Recordati; Xeris; Corcept; Sparrow, Nature of Relationship: Institution-directed research support for clinical trial participation \/ Amryt\/Chiesi; Crinetics; Xeris; HRA Pharma; Sparrow; Recordati; and Lundbeck, Nature of Relationship: Scientific Consulting\/Advisory Boards. G.E.F. is a co-author of the ASBMR-BHOF Goal-Directed Osteoporosis Treatment position statement. G.F has received research grants to study obesity from competitive funding bodies: Fondo Investigaci\u00f3n Sanitaria (FIS), CIBEROBN, and the Spanish Institute of Health & EU Funds. A.C. has received honoraria from Novo Nordisk, Eli Lilly, Astra Zeneca, Sanofi Aventis, ESTEVE, ZAMBON, and Boehringer Ingelheim, and Advisory Board from Eli Lilly, Novo Nordisk, and Boehringer Ingelheim. Data monitoring committee Boehringer Ingelheim. C.S. provides consulting services to STEROTHERAPEUTICS, Inc. and works with HUMAN LONGEVITY, ASTREA Health and Healthspan Digital, all private entities in the field of genetics. He has also received research support from Pfizer, Inc. All the above are unrelated to the content of this article. J.W reports consultancy \/ advisory board work for the pharmaceutical industry contracted via the University of Liverpool (no personal payment) for Altimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Cytoki, Lilly, Napp, Novo Nordisk, Menarini, Pfizer, Rhythm Pharmaceuticals, Sanofi, Saniona, Tern, & Shionogi; research grants for clinical trials from AstraZeneca and Novo Nordisk and personal honoraria \/ lecture fees from AstraZeneca, Boehringer Ingelheim, Medscape, Novo Nordisk, and Rhythm. He is past president of the World Obesity Federation, a member of the Association for the Study of Obesity, Diabetes UK, EASD, ADA, Society for Endocrinology and the Rank Prize Funds Nutrition Committee. From 2009 to 2024 he was national lead for the Metabolic and Endocrine Specialty Group of the UK NIHR Clinical Research Network. E.A. is an advisory board member of Astellas and Besins Healthcare. C.H has received lecture fees from Novo Nordisk, Sandoz, and Pfizer. G.T has had a conflict of interest over the last 3 years regarding the topic \u201cLecture fees from Novo Nordisk, Medtronic, Sanofi.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}